Showing 2,021 - 2,040 results of 101,820 for search '(( 2 step decrease ) OR ( 5 ((((nn decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.48s Refine Results
  1. 2021
  2. 2022

    Fluorescence of 5-Arylvinyl-5′-Methyl-2,2′-Bipyridyl Ligands and Their Zinc Complexes by Ali H. Younes (1589731)

    Published 2009
    “…The photophysical properties of 5-arylvinyl-5′-methyl-2,2′-bipyridyls (AVMBs, <b>1</b>−<b>9</b>, <b>11</b>) and their zinc complexes were studied. …”
  3. 2023

    Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA<sub>1</sub>/LPA<sub>3</sub> antagonist. by Masahiko Kanehira (183764)

    Published 2012
    “…Human MSCs at passage 2 were cultured in the presence or absence of Ki16425 for the indicated days prior to cell lysis. Fold-change represents decrease in band intensity of Ki16425 treatment for 18 days compared with a control treatment for the same period of time. …”
  4. 2024
  5. 2025
  6. 2026
  7. 2027

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  8. 2028

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  9. 2029
  10. 2030
  11. 2031
  12. 2032
  13. 2033
  14. 2034
  15. 2035
  16. 2036
  17. 2037
  18. 2038
  19. 2039
  20. 2040

    Pharmacodynamic Profile of CCX168 in Healthy Human Volunteers. by Pirow Bekker (392139)

    Published 2016
    “…CD11b upregulation was diminished in both blood samples from CCX168 subjects with a 10-fold decrease in C5a potency exhibited in the 12-hour samples.…”